3 results
Primary objective: to determine the biological activityof Hespecta that is able to induce HPV16 E6-specific T-cell immunity within a proposed dose escalation of 1, 5, 20 or 50 µg/peptide - conjugate in patients treated for HPV16+ OSCC.Secondary…
Primary objective:To evaluate the safety and tolerability of KY1005.Secondary objectives:To evaluate the pharmacokinetics (PK) of KY1005 following single and repeat doses.Exploratory objectives:- To evaluate the immunogenicity of KY1005;- To assess…
PRIMARYTo demonstrate an effect of recAP on 28-day all-cause mortality.SECONDARY1. To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE).2. To investigate the effect of recAP on use of organ support, i.e., mechanical…